Ovarian Cancer | Tumor

CURE’s ovarian cancer page is a go-to resource for oncology news and updates in the world of ovarian cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in ovarian cancer.

CURE Magazine Teams Up with the Foundation for Women's Cancer in Advocacy Spotlight Partnership Program

June 25th 2015, 11:57pm

Article

CURE Magazine and the Foundation for Women's Cancer have teamed up in CURE's Advocacy Spotlight Partnership program to battle women's cancer through education and shared advocacy on behalf of women suffering from below-the-belt women's cancers.

An Expedition Through Cancer

June 12th 2015, 10:09pm

Article

Backpacking through Nepal, two magicians discover a life-changing secret.

Rucaparib Elicits High Response Rate in BRCA-Mutant Ovarian Cancer

June 10th 2015, 11:39pm

Article

Treatment with a new PARP inhibitor called rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer.

Two-Pronged Strategy With PARP Inhibitor Gains Traction in Breast and Ovarian Cancers

May 8th 2015, 7:46pm

Article

A two-pronged strategy combining the PARP inhibitor Lynparza and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with TNBC and for patients with high-grade serous ovarian cancer.

Empowering Patients Along Their Cancer Journey

May 8th 2015, 6:14pm

Article

An oncology nurse navigator writes about her patient's journey with ovarian cancer.

More Women at High Risk of Ovarian Cancer Opt to Take Action Following Genetic Counseling

May 8th 2015, 1:23am

Article

Women who are at high risk of ovarian cancer are more likely to undergo preventive ovary removal if they are proactively offered genetic counseling, a new study has found.

Making Progress in the Treatment of Ovarian Cancer

May 2nd 2015, 1:00am

Article

While surgical advances and new treatment approvals, including Lynparza and Avastin, have improved the outlook in ovarian cancer, late diagnosis and tumor resistance remain as significant barriers to major progress in treating the disease.

Fosbretabulin and Avastin Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer

April 1st 2015, 1:12am

Article

Pretreated patients with recurrent ovarian cancer had a 2.5-month progression-free survival benefit when receiving fosbretabulin plus Avastin compared with Avastin alone; however, hypertension rates doubled.

Avastin Regimen Shows Survival Trend in Phase 3 Ovarian Cancer Trial

March 30th 2015, 10:08pm

Article

Treatment with Avastin plus chemotherapy resulted in an improvement in overall survival of nearly five months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015, 8:25pm

Article

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage 3/4 ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not, according to an open-label phase 2 trial.